I share the desire for a quick buck, but I'm sure that CYP would be worth more long term in our hands than anything we'd get in a TO. So for Ross, who has to get the best deal for shareholders, maybe continuing that business model is the best long term. If it is attractive enough to be taken over then imagine how we would be rerated with a number of companies licensing our tech to produce their cells. Risk is on them once we've proven things out completely.
W
Add to My Watchlist
What is My Watchlist?
